Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study

Cascini, Giuseppe Lucio; Falcone, Cristina; Console, Domenico; Restuccia, Antonino; Rossi, Marco; Parlati, Antonello; Tamburrini, O

doi:10.1007/s11547-013-0946-7

Cited by 35 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of MRI on staging patients according to DS Plus has been analyzed in many studies [ 12 – 14 ]. Although 18 F-FDG PET/CT has been proved to be prognostically valuable in staging different groups [ 15 – 17 ], only few studies have been reported on DS Plus based on 18 F-FDG PET/CT [ 18 ]. One of the reasons is that no standard interpretation criteria have been proposed for the evaluation of 18 F-FDG PET/CT scans in MM.…”

Section: Discussionmentioning

confidence: 99%

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

Deng

Zhang

Zhou

et al. 2018

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

We aimed at comparing the Durie–Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMPeTUs) with other two staging systems in predicting prognosis of patients with all stages of newly diagnosed multiple myeloma (MM). A total of 33 MM patients were enrolled in this retrospective study. The variation between the DS Plus classification and Durie–Salmon staging system (DSS) or Revised International Staging System (RISS) classification was assessed. When staged by the DSS, patients in stage I and stage II did not reach the median overall survival (OS), and the median OS was 33 months for stage III (p=0.3621). When staged by the DS Plus, patients in stage I did not reach the median OS of stage I, and the median OS for stages II and III was 38 and nine months, respectively (p=0.0064). When staged by the RISS, patients in stage I did not reach the median OS, and the median OS was 33 and 16 months for stage II and stage III, respectively (p=0.0319). The concordances between two staging systems were 0.07 (DS Plus versus DSS) and 0.37 (DS Plus versus RISS), respectively. Multivariate analysis revealed that DS Plus stage III (HR: 11.539, p=0.021) and the Deauville score of bone marrow ≥4 (HR: 3.487, p=0.031) were independent prognostic factors associated with OS. Both the DS Plus based on IMPeTUs and RISS possessed a better potential in characterizing and stratifying MM patients compared with the DSS. Moreover, DS Plus stage III and the Deauville score of bone marrow ≥4 were reliable prognostic factors in newly diagnosed MM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

Deng

Zhang

Zhou

et al. 2018

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Thus, the authors posited that MR imaging appears to be the superior study in terms of diagnostic performance (54). A prospective study of 22 patients with newly diagnosed multiple myeloma who underwent PET/CT and whole-body MR imaging prior to treatment showed PET/CT findings to be positive in 18 of 22 cases, whereas MR imaging findings were positive in all patients (55). These results again support the diagnostic power of MR imaging.…”

Section: Use Of Mr Imaging and Pet/ct In Staging And Diagnosismentioning

confidence: 84%

“…PET/CT has been found to be more sensitive than MR imaging in treatment assessment. In one analysis, PET/CT helped correctly identify 16 of 20 patients who had a positive response to treatment, compared with only 12 of 20 patients at MR imaging (55). PET/CT also demonstrates much faster normalization of imaging findings than does MR imaging.…”

Section: Use Of Mr Imaging and Pet/ct In Staging And Diagnosismentioning

confidence: 99%

MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma

et al. 2015

View full text Add to dashboard Cite

Multiple myeloma is a common hematologic malignancy among the elderly population. Although there have been many advances in treatment over the past few decades, the overall prognosis for the disease remains poor. Conventional radiography has long been the standard of reference for the imaging of multiple myeloma. However, 10%-20% of patients with multiple myeloma do not have evidence of disease at conventional radiography. There is a growing body of evidence supporting use of magnetic resonance (MR) imaging and 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) in diagnosis and management of multiple myeloma. MR imaging is useful in detection of bone marrow infiltration, a finding often missed at conventional radiography. FDG PET/CT is especially sensitive for the detection of extramedullary disease and can help detect the metabolically active lesions that often precede evidence of osseous destruction at conventional radiography. MR imaging and FDG PET/CT are useful tools that can provide essential information for diagnosis and management of patients with multiple myeloma. Both modalities allow accurate localization of disease after chemotherapy or autologous stem cell transplantation and can provide important prognostic information that can influence further clinical decision making regarding therapy, particularly when tumor serum markers may be a less reliable indicator of disease burden after repeated treatments.

show abstract

“…Studies have demonstrated that WB-MRI has a greater sensitivity and specificity for detection of focal bone lesions in myeloma compared with both WB-CT ( n = 41) 6 and 18 F-FDG PET/CT ( n = 22). 7…”

Section: Discussionmentioning

confidence: 99%

National survey of imaging practice for suspected or confirmed plasma cell malignancies

Westerland

Pratt

Kazmi

et al. 2018

The British Journal of Radiology

View full text Add to dashboard Cite

This is the first publication to date evaluating current UK imaging practice for assessing myeloma since the publication of new guidelines recommending use of advanced cross-sectional imaging techniques. Skeletal survey remains the most commonly performed first-line imaging test in patients with suspected or confirmed myeloma and this is largely due to resource limitations within radiology departments.

show abstract

Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study

Abstract: WB-MRI proved superior to PET/CT in detecting MM, especially in diffuse disease. PET/CT appears to be more sensitive in the assessment of MM after treatment.

Cited by 35 publications

References 46 publications

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma

National survey of imaging practice for suspected or confirmed plasma cell malignancies

Contact Info

Product

Resources

About

Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study

Abstract: WB-MRI proved superior to PET/CT in detecting MM, especially in diffuse disease. PET/CT appears to be more sensitive in the assessment of MM after treatment.

Cited by 35 publications

References 46 publications

The Role of18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

The Role of18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma

National survey of imaging practice for suspected or confirmed plasma cell malignancies

Contact Info

Product

Resources

About

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

The Role of¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems